Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
Newly approved CAR-T therapy offers hope for leukemia patients whose cancers resist standard drug treatments.
This review comprehensively examines emerging treatments for CLL refractory to both BTK inhibitors and BCL-2 inhibitors. It highlights lisocabtagene maraleucel as a potentially curative FDA-approved CAR-T option and promising data on noncovalent BTKi and bispecific antibodies.
What the study was
- Study design
- Narrative review
- Population
- Double refractory CLL patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Clinically relevant review of an urgent unmet need (double refractory CLL). Review format limits score vs. primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.